Loading…
Aardvark Therapeutics, Inc. is projected to rise to $8.73 by 2027, a +15% move from its current price of $7.60. AARD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $7.09 | $7.60 | $8.16 | +0.03% |
| Jul 13 | $6.89 | $7.60 | $8.40 | +0.06% |
| Jul 14 | $6.74 | $7.61 | $8.59 | +0.09% |
| Jul 15 | $6.61 | $7.61 | $8.76 | +0.11% |
| Jul 16 | $6.51 | $7.61 | $8.90 | +0.14% |
| Jul 17 | $6.41 | $7.61 | $9.04 | +0.17% |
| Jul 18 | $6.32 | $7.62 | $9.17 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.32 | $7.62 | $9.17 | +0.20% |
| Week 2 | $5.87 | $7.63 | $9.92 | +0.40% |
| Week 3 | $5.54 | $7.65 | $10.55 | +0.60% |
| Week 4 | $5.28 | $7.66 | $11.11 | +0.80% |
| Week 5 | $5.07 | $7.68 | $11.63 | +1.00% |
| Week 6 | $4.88 | $7.69 | $12.12 | +1.20% |
| Week 7 | $4.71 | $7.71 | $12.60 | +1.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The description places the company in the Healthcare sector and notes its incorporation in 2017 with headquarters in San Diego, California.
The company trades under the symbol AARD and operates within the healthcare industry. Its positioning reflects a clinical-stage entity focused on metabolic disease therapeutics, with a clearly defined corporate identity in the healthcare space.
Aardvark Therapeutics, Inc. (AARD) currently trades at $7.60, with a market cap of $165.8M and a rank of 3913. This places the stock as a smaller-cap name within the healthcare landscape, with the current price reflecting mid-range momentum metrics in the near term.
The 30-day technical range runs from $4.78 to $12.07, and the stock carries bullish sentiment in the 14-day window. Key levels include a support of $3.48 and a resistance of $7.60, with moving averages indicating a near-term dynamic between $4.79 on SMA50 and $9.19 on SMA200. The current price context sits against a backdrop of volatility, reflecting the 100% annualized volatility figure.
Forecasts show an evolving path for AARD beginning in 2026, with the 2026 average price at $7.60, followed by progressively higher yearly averages through 2030 and beyond. The long-range outlook projects substantial upside, with 2030 and later years generating increasingly large average prices and ROI figures, culminating in a very strong long-term trajectory.
A major floor 72.3% below — a decisive break under it would weaken the trend.
The nearest floor, 54.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 36.1% above — clearing it would confirm fresh momentum.
Key AARD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AARD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.86 | Buy | $6.07 | Buy |
| MA 10 | $5.64 | Buy | $5.65 | Buy |
| MA 20 | $4.88 | Buy | $5.19 | Buy |
| MA 50 | $4.79 | Buy | $5.06 | Buy |
| MA 100 | $5.48 | Buy | $6.08 | Buy |
| MA 200 | $9.19 | Sell | $7.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 73.53 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 228.55 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.20 | Buy |
| ROC (12) | 79.67 | Buy |
| Bollinger %B (20,2) | 1.19 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 1.36 | Buy |
| Ultimate (7,14,28) | 73.98 | Sell |
| Momentum (10) | 2.54 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 5.82 | Buy |
| ADX (14) | 24.21 | Buy |
| ATR (14) | 0.42 | Info |
The 30-day picture remains bullish, with RSI14 at 70 signaling upside momentum within a positive trend.
Moving averages place near-term price behavior between $4.79 on the SMA50 and $9.19 on the SMA200, highlighting a divergent path between short- and longer-term averages. Support is marked at $3.48 and resistance at $7.60, shaping a compact near-term trading window.
The 30-day price range spans from $4.78 to $12.07, underscoring notable volatility while the current setup leans toward upside bias on a near-term horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.48 | $7.60 | $11.15 | 0% | Neutral | |
| $6.28 | $8.73 | $13.12 | +15% | Neutral | |
| $6.31 | $9.35 | $15.00 | +23% | Bullish | |
| $6.03 | $9.43 | $15.91 | +24% | Bullish | |
| $8.54 | $14.04 | $24.68 | +85% | Bullish | |
| $10.48 | $18.05 | $32.88 | +138% | Bullish | |
| $10.58 | $19.05 | $35.79 | +151% | Bullish | |
| $12.71 | $23.88 | $46.16 | +214% | Bullish | |
| $11.43 | $22.41 | $44.44 | +195% | Bullish | |
| $9.90 | $20.23 | $41.07 | +166% | Bullish | |
| $17.74 | $39.42 | $88.11 | +419% | Bullish | |
| $31.26 | $69.47 | $159.78 | +814% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.48 | $7.60 | $9.09 | +0.00% |
| August 2026 | $5.96 | $7.23 | $9.16 | -4.82% |
| September 2026 | $6.33 | $7.80 | $10.09 | +7.82% |
| October 2026 | $6.65 | $8.30 | $10.92 | +6.36% |
| November 2026 | $6.44 | $8.13 | $10.87 | -1.99% |
| December 2026 | $6.46 | $8.23 | $11.15 | +1.23% |
Click any year to see its month-by-month AARD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aardvark Therapeutics, Inc.'s 2026 outlook centres on $7.60, within a $3.48 to $11.15 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AARD could reach as high as $13.12, with a base case around $8.73 and support toward $6.28 — roughly +15% from $7.60. Price action looks broadly range-bound.
Expect AARD to range from $6.31 to $15.00 through 2028. The $9.35 average target implies a +23% move from current prices. That is up +7% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The AARD price prediction for 2029 points to an average of $9.43 (low $6.03, high $15.91) — a potential gain of +24% on today's $7.60. Momentum favours further upside here.
In 2030, AARD is projected to trade between $8.54 and $24.68, averaging $14.04 — a potential gain of +85% from today's $7.60. That is up +49% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Aardvark Therapeutics, Inc.'s 2031 outlook centres on $18.05, within a $10.48 to $32.88 range. That is up +29% on the projected 2030 average. That marks a +138% change versus current levels. Momentum favours further upside here.
By 2032, AARD could reach as high as $35.79, with a base case around $19.05 and support toward $10.58 — roughly +151% from $7.60. Buyers look set to stay in control over this stretch.
Expect AARD to range from $12.71 to $46.16 through 2033. The $23.88 average target implies a +214% move from current prices. That is up +25% on the projected 2032 average. Momentum favours further upside here.
The AARD price prediction for 2034 points to an average of $22.41 (low $11.43, high $44.44) — a potential gain of +195% on today's $7.60. Buyers look set to stay in control over this stretch.
In 2035, AARD is projected to trade between $9.90 and $41.07, averaging $20.23 — a potential gain of +166% from today's $7.60. That is -10% versus the projected 2034 average. Momentum favours further upside here.
Aardvark Therapeutics, Inc.'s 2040 outlook centres on $39.42, within a $17.74 to $88.11 range. That is up +95% on the projected 2035 average. That marks a +419% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AARD could reach as high as $159.78, with a base case around $69.47 and support toward $31.26 — roughly +814% from $7.60. Momentum favours further upside here.
Investing $1,000 in AARD today (≈ 131.578947 AARD) could be worth
$9,140.71
+$8,140.71 (+814%) by 2050 · US Dollar
Based on the average projected AARD price of $69.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AARDwould be worth at today's price.
$1,000 invested in AARD on Jul 10, 2025 (≈ 79.365077 AARD) would be worth
$603.17
-$396.83 (-39.7%) today · 0.60× · US Dollar
Based on a AARD entry price of $12.6 vs. today's $7.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.7 | $1,333.33 | +33.3% |
| 1 month ago | $3.48 | $2,183.91 | +118.4% |
| 3 months ago | $3.94 | $1,928.93 | +92.9% |
| 6 months ago | $14.84 | $512.13 | -48.8% |
| 1 year ago | $12.6 | $603.17 | -39.7% |
| All time (1.4y) ago | $14.31 | $531.1 | -46.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AARD forecast.
Our base-case forecast reaches $15.00 around 2031.
Implied market cap at $15.00: $327.25M
The multi-year forecast paints a compelling bullish arc after a cautious start in 2026. The 2030 average price is projected at $14.04 with a max of $24.68 and a min of $8.54, delivering an 84.8% ROI and a bullish sentiment. By 2040, the average price is expected to reach $39.42 with a max of $88.11 and a min of $17.74, yielding a 418.7% ROI in that year’s context while remaining bullish.
Looking further out to 2050, the average price is forecast at $69.47 with a max of $159.78 and a min of $31.26, producing an 814.1% ROI. The 2031–2033 period continues the bullish thread, with progressively higher averages and sizable ROIs, underscoring strong long-run upside potential albeit with inherent uncertainty. These forecasts are estimates, not guarantees, and depend on market conditions and future developments.
Tap a question to reveal the answer.
2030 forecast: min $8.54, avg $14.04, max $24.68; ROI 84.8%; sentiment BULLISH.
Near term shows neutral sentiment in 2026 (avg $7.60) and 2027 (avg $8.73), with bullish momentum building by 2028 (avg $9.35) and 2029 (avg $9.43). The 2030 avg is $14.04 with ROI 84.8% and a bullish outlook continuing into later years, with higher ROIs projected (e.g., 2040 ROI 418.7% and 2050 ROI 814.1%). These are estimates, not guarantees.
Yes. The 2040 forecast shows an average near $39.42 and a max of $88.11, while 2050 projects an average of $69.47 with a max of $159.78, and a 814.1% ROI. A price of $50 sits between these projected levels in the longer term.
Current price is $7.60 and market cap is $165.8M.
The short-term setup shows bullish sentiment, RSI14 at 70, SMA50 at $4.79, SMA200 at $9.19, support at $3.48 and resistance at $7.60. The 30-day range is $4.78–$12.07.
Aardvark Therapeutics, Inc. Community Discussion
0Share your Aardvark Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.